Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Ralco Nutrition Inc. operates within the Biotechnology & Pharmaceuticals technology area and currently has 1 pending office action. This action is being handled by BAEK, BONG-SOOK, who is identified as the busiest examiner for the company with 1 pending matter. The prosecution landscape for this portfolio is extremely focused, involving only 1 distinct examiner and 1 distinct art unit. This concentration means that the 1 pending office action represents the entirety of the company's current interaction with the USPTO.
Practitioners can expect a singular point of contact for the Biotechnology & Pharmaceuticals claims, as no other art units or examiners are currently engaged in the company's pending workload. The reliance on 1 distinct examiner and 1 distinct art unit suggests that the company's patent strategy is highly specialized. This lack of diversification means that the 1 distinct examiner's interpretation of the Biotechnology & Pharmaceuticals field will be the primary factor in the success of the 1 pending office action. For the practitioner, this necessitates a deep understanding of the specific examiner's past rulings and the technical standards of the 1 distinct art unit involved.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAEK, BONG-SOOK | 1 | 41.6% | +69.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17215677 | FEED MITIGANT COMPOSITIONS FOR INACTIVATING SWINE VIRUSES AND RELATED METHODS | BAEK, BONG-SOOK | 6d |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17215677 | FEED MITIGANT COMPOSITIONS FOR INACTIVATING SWINE VIRUSES AND RELATED METHODS | BAEK, BONG-SOOK | 1611 | §103DP | Final Rejection | 6d | Pending | Mar 29, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRalco Nutrition Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Bong-Sook Baek has the most, with 1 of Ralco Nutrition Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
